Biodexa Pharmaceuticals Plc

BST:5MPA Stock Report

Market Cap: €2.9m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Biodexa Pharmaceuticals Valuation

Is 5MPA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 5MPA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 5MPA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 5MPA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 5MPA?

Key metric: As 5MPA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 5MPA. This is calculated by dividing 5MPA's market cap by their current revenue.
What is 5MPA's PS Ratio?
PS Ratio3.6x
SalesUK£699.00k
Market CapUK£2.52m

Price to Sales Ratio vs Peers

How does 5MPA's PS Ratio compare to its peers?

The above table shows the PS ratio for 5MPA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average79.2x
CNW co.don
0.7xn/a€6.5m
T5O bioXXmed
311.8xn/a€1.6m
BPXA Bellicum Pharmaceuticals
0.5xn/a€772.4k
SBH Sangui Biotech International
3.8xn/a€419.8k
5MPA Biodexa Pharmaceuticals
3.6xn/a€3.1m

Price-To-Sales vs Peers: 5MPA is good value based on its Price-To-Sales Ratio (3.6x) compared to the peer average (7.8x).

Price to Sales Ratio vs Industry

How does 5MPA's PS Ratio compare vs other companies in the DE Biotechs Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIO3 Biotest
1.3x-4.1%US$1.42b
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
5MPA 3.6xIndustry Avg. 7.9xNo. of Companies7PS0612182430+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 5MPA is good value based on its Price-To-Sales Ratio (3.6x) compared to the European Biotechs industry average (8.1x).

Price to Sales Ratio vs Fair Ratio

What is 5MPA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

5MPA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.6x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 5MPA's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Almirall

€1.8b

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

E2Z

€8.46

7D

-3.4%

1Y

2.1%

Pharming Group

€498.9m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.71

7D

-1.0%

1Y

-32.7%

Merck

US$249.2b

Operates as a healthcare company worldwide.

6MK

US$93.10

7D

-1.0%

1Y

-0.1%